Iambic Therapeutics raises $150M in US IPO at $16 per share

Iambic Therapeutics, an AI-powered drug discovery startup backed by Nvidia, raised $150 million in its US initial public offering. The San Diego-based company sold 9.38 million shares at $16 each, according to NewsBytes.

The offering follows Iambic’s Nasdaq IPO filing last month, which we first reported on 22 September. The startup uses machine-learning models to design small-molecule therapies, positioning itself among a growing group of AI biotechs aiming to speed up drug development. Nvidia’s backing highlights the role of high-performance computing in training and refining these models.

Iambic’s IPO comes as AI-driven biotech faces scrutiny. While venture funding for the space continues—London-based Big Picture Bio recently secured €2.55 million for AI-designed cancer drug combinations—public markets have been selective about the category. How Iambic’s pipeline progresses could influence broader investor sentiment.

The $150 million raise aligns with other large funding rounds, such as SiMa.ai’s recent $150 million for embedded AI chips, though Iambic’s focus on drug development may appeal to different investors. The IPO’s pricing suggests public markets are approaching these companies with caution, particularly those with early-stage pipelines.

What happens next will depend on Iambic’s ability to show meaningful progress. For now, the IPO reflects the sector’s momentum but also its challenges.

Sources: newsbytesapp.com